Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial

A randomized controlled trial published in Nature has found that dronabinol, a synthetic form of THC, can significantly reduce trauma-related nightmares in patients with post-traumatic stress disorder. The study, conducted by Charité, is the first to demonstrate the efficacy of THC in treating PTSD-related nightmares.

The findings are particularly relevant as PTSD affects millions worldwide, with nightmares being a common and debilitating symptom. The trial's results have sparked interest in the medical community, with The Clinical Trial Vanguard discussing the implications for central nervous system trial design.

The Vermont Community Newspaper Group and Neuroscience News have also covered the story, focusing on the potential benefits for PTSD patients. The next steps involve further research to confirm these findings and explore the long-term effects of THC treatment on PTSD symptoms.